{\rtf1\ansi\deff0\deftab360

{\fonttbl
{\f0\fswiss\fcharset0 Arial}
{\f1\froman\fcharset0 Times New Roman}
{\f2\fswiss\fcharset0 Verdana}
{\f3\froman\fcharset2 Symbol}
}

{\colortbl;
\red0\green0\blue0;
}

{\info
{\author Biblio 7.x}{\operator }{\title Biblio RTF Export}}

\f1\fs24
\paperw11907\paperh16839
\pgncont\pgndec\pgnstarts1\pgnrestart
D.  Bose, Jayaraj, G. Gunanathan, Suryawanshi, H., Agarwala, P., Pore, S. Kumar, Banerjee, R., and Maiti, S., ?Tuberculosis drug streptomycin as a potential cancer therapeutic: inhibition of miR-21 function by directly targeting its precursor?, Angewandte Chemie-International Edition, vol. 51, no. 4, pp. 1019-1023, 2012.\par \par P.  Prakash, Vijayasarathi, D., Selvam, K., Karthi, S., and Manivasagaperumal, R., ?Pharmacore maping based on docking, ADME/toxicity, virtual screening on 3,5-dimethyl-1,3,4-hexanetriol and dodecanoic acid derivates for anticancer inhibitors?, Journal of Biomolecular Structure & Dynamics, vol. 39, no. 12, pp. 4490-4500, 2021.\par \par P. D.  Kunde, Ramkumar, S., Kamble, S. P., RaviKumar, A., Kulkarni, B. D., and V. Kumar, R., ?On the use of electronegativity and electron affinity based pseudo-molecular field descriptors in developing correlations for quantitative structure-activity relationship modeling of drug activities?, Chemical Biology & Drug Design, vol. 98, no. 2, pp. 258-269, 2021.\par \par D.  Kumari, Kour, J., Kumar, A., Sangral, M., Singh, S. K., Sawant, S. D., and Singh, K., ?Novel pyrazole derivatives as inhibitors of Leishmania donovani: an integrated approach combining in vitro analysis and mechanistic insights?, Bioorganic Chemistry, vol. 164, p. 108804, 2025.\par \par S. Sai N. Saranya, Choudhury, R., Routholla, G., Supekar, P. R., R, N., Martin, A. Kuriyickal, Muruganandham, R. Devi, Kumar, B. Kiran, and D. Reddy, S., ?Ready access to benzodiazocines from tryptamines: a druggable scaffold toward antiviral agents?, ACS Medicinal Chemistry Letters, vol. 16, no. 12, pp. 2362-2367, 2025.\par \par }